As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Doxorubicin has the largest established regional market in North America. This dominance can be attributed to the highest global incidence of cancer cases and the growing number of research facilities, as well as pharmaceutical companies working to counter the disease. Cancer can usually be detected only at the later stages owing to the lack of evident symptoms of the disease in its nascent stages. Hence, the drug has extensive use in the region that results in a comparatively lower mortality rate. Further, the most common application of doxorubicin is found in the disease segment of breast cancer, which accounts for the largest share of cancer cases worldwide. Since the mortality rate associated with breast cancer is relatively low, doxorubicin application is extensive in the segment due to the higher chances of survival. According to the statistics, the mortality rate associated with breast cancer was 30.3% in 2020, which is the lowest among all the causes. Hence, the growth of this application segment is estimated to continue over the forecast period.
In April 2020, the National Cancer Institute (NCI), United States, announced the identification of an experimental drug called BAI1, which is found to protect against cardiomyopathy, which is a side effect of consuming doxorubicin, potentially leading to heart failure. This will not only improve the treatment for cancer patients but also counter the hurdle against the market growth for doxorubicin. More recently, in June 2021, a team led by Dr. Ju Hee Ryu of the Centre for Theragnosis at the Korea Institute of Science and Technology (KIST) announced the development of a prodrug for anti-cancer immunotherapy that utilises the immunity-boosting potential of doxorubicin. This development will reduce the toxic effect of doxorubicin on normal cells reducing its side effects to a great extent. In addition to this, healthy competition among the industry key players, such as Pfizer Inc. (NYSE: PFE) and Sun Pharmaceutical Industries Limited, is expected to augment the market growth over the market growth.
Market Analysis by Application and Region:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global doxorubicin market are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.